Full-length genomic DNA of the recently identified laboratory mouse papillomavirus 1 (MusPV1) was synthesized in vitro and was used to establish and characterize a mouse model of papillomavirus pathobiology. MusPV1 DNA, whether naked or encapsidated by MusPV1 or human papillomavirus 16 (HPV 16) capsids, efficiently induced the outgrowth of papillomas as early as 3 weeks after application to abraded skin on the muzzles and tails of athymic NCr nude mice. High concentrations of virions were extracted from homogenized papillomatous tissues and were serially passaged for >10 generations. Neutralization by L1 antisera confirmed that infectious transmission was capsid mediated. Unexpectedly, the skin of the murine back was much less susceptible to virion-induced papillomas than the muzzle or tail. Although reporter pseudovirions readily transduced the skin of the back, infection with native MusPV1 resulted in less viral genome amplification and gene expression on the back, including reduced expression of the L1 protein and very low expression of the L2 protein, results that imply skin region-specific control of postentry aspects of the viral life cycle. Unexpectedly, L1 protein on the back was predominantly cytoplasmic, while on the tail the abundant L1 was cytoplasmic in the lower epithelial layers and nuclear in the upper layers. Nuclear localization of L1 occurred only in cells that coexpressed the minor capsid protein, L2. The pattern of L1 protein staining in the infected epithelium suggests that L1 expression occurs earlier in the MusPV1 life cycle than in the life cycle of high-risk HPV and that virion assembly is regulated by a previously undescribed mechanism.
P apillomaviruses (PVs) comprise a group of nonenveloped, double-stranded DNA viruses that infect the epithelial cells of humans and numerous vertebrate animal species, generally causing benign papillomas and warts on the skin and mucous membranes of their respective host species. In addition, some PV types have oncogenic potential and are responsible for the development of malignancies of the anogenital tract and other epithelial sites (1) .
The study of animal PVs, especially cottontail rabbit papillomavirus (CRPV), canine oral papillomavirus (COPV), and the bovine papillomaviruses (BPV), has made important contributions to the current knowledge of PV infection and diseases, the PV life cycle and pathogenesis, and vaccine efficacy (reviewed in reference 2). However, major limitations of these models include the large size of the animal hosts and the restricted availability of biological, genetic, and immunological markers and reagents for these species. PV investigation would be facilitated by a PV model in a smaller species that is easy to handle, is cost-effective to house, and has a shorter generation time, and for which reagents are widely available. In this regard, laboratory mice represent the most extensively characterized nonhuman species, and many molecular, genetic, and immunological reagents are available.
Several PVs that infect rodents have been identified. The first was isolated from the African multimammate rat (Mastomys coucha, previously assigned to the Mastomys natalensis species) and was termed MnPV (3) . An additional PV type, designated McPV2, was subsequently found in these animals (4) . These two viruses cause spontaneous lesions at distinct anatomical sites: MnPV is responsible for the development of benign skin papillomas and keratoacanthomas, occurring in 30 to 40% of animals at the age of 1 year, and McPV2 for benign papillomas on the anogenital mucosa, found in 7 to 8% of animals by the age of 8 months (4) . Other rodent PVs include MaPV1 (previously named hamster oral papillomavirus [HOPV] ), identified in the Syrian golden hamster (Mesocricetus auratus) (5) , EdPV1 in the North American porcupine (Erethizon dorsatum) (6) , and RnPV1 and RnPV2 in Norway rats (Rattus norvegicus) (7, 8) . Two mouse-associated PVs are MmPV, isolated from the European harvest mouse (Micromys minutus) (9, 10) , and the more recently identified AsPV1, found in the wood mouse (Apodemus sylvaticus) (8) .
PV infection is characteristically species specific, although some interspecies transmission may occur spontaneously or experimentally. Infection of heterologous hosts usually results either in reduced virus production, as with experimental infection of domestic rabbits by CRPV (reviewed in reference 11), or in nonproductive transformation of dermal fibroblasts, as with spontaneous or experimental infection of horses by BPV type 1 (reviewed in reference 12). However, the rodent viruses described above have not been reported to induce lesions in laboratory mice (Mus musculus) or to infect them.
Therefore, the report of the first known PV that can cause lesions in the domestic mouse (Mus musculus) represented a potentially important advance (13) . The virus was identified in an immunodeficient, inbred NMRI-Foxn1 nu /Foxn1 nu nude mouse colony and was termed MusPV1. In the infected colony, mice spontaneously developed papillomas at cutaneous surfaces near the mucocutaneous junctions of nose and mouth, and infectious MusPV1 virions isolated from these lesions induced papilloma formation on the muzzles of immunodeficient B6.Cg-Foxn1 nu / Foxn1 nu mice (14) . The papillomas showed typical histologic features of PV-associated lesions and expressed PV group-specific antigens. A recent report has confirmed the ability of the MusPV1 genome to induce papillomas in Foxn1 nu /Foxn1 nu mice (15) . The presence of large arrays of virus particles in lesional keratinocytes (13, 14) , together with the recent identification of an MusPV1 variant, displaying 99% nucleotide identity to the original MusPV1, in normal skin from a German house mouse (8) , supports the conclusion that MusPV1 is a bona fide domestic mouse virus.
Because infectious MusPV1 virions were not made available after the original publication, we have synthesized the MusPV1 DNA genome in vitro and established an experimental MusPV1 model by initially inoculating immunodeficient mice with naked synthetic viral DNA or quasivirions produced in cultured cells in which the synthetic DNA was encapsidated by L1/L2 capsids. The synthetic DNA was shown to induce papillomas and to drive the production of native MusPV1 virions, thus allowing in vitro and in vivo studies independent of the naturally occurring viral source. Here we stringently fulfill Koch's postulates by demonstrating serial viral transmission of papillomas in vivo, and we characterize the infectious and pathological properties of MusPV1 in its natural host species. In addition, unexpected skin site tropism and late gene expression patterns are documented.
MATERIALS AND METHODS
Generation of the full-length MusPV1 genome, MusPV1 pseudovirions (PsV), and quasivirions. The sequence of the prototype MusPV1 genome (16) (GenBank accession no. GU808564) was chemically synthesized in six fragments. The fragments were joined using a series of restriction enzyme-based cloning steps, and the full-length MusPV1 genome was transferred into the XbaI site of pAsylum (17) . The integrity of the clone generated was verified by sequencing.
The viral genome was recovered by excision from the plasmid backbone using the restriction enzyme XbaI, followed by intramolecular religation using T4 DNA ligase, as detailed on the website of the Laboratory of Cellular Oncology (http://home.ccr.cancer.gov/Lco).
To generate quasivirions for in vivo transmission experiments, 293TT cells (18) were used to package the religated full-length MusPV1 genome into L1 and L2 capsid proteins expressed from codon-modified genes of either the homologous virus MusPV1 (19) or the heterologous virus HPV 16. This procedure generated MusPV1 L1/L2 MusPV1 or HPV 16 L1/L2 MusPV1 quasivirions, respectively.
For in vivo imaging analysis and for in vitro standard neutralization assays, MusPV1 L1/L2 PsV containing either the pCLucf reporter plasmid, harboring a firefly luciferase expression cassette (20) , or the phGluc reporter plasmid, encoding Gaussia luciferase (21), were produced. Each reporter plasmid was encapsidated into codon-modified L1 and L2 capsid proteins of MusPV1 (19) .
Quasivirions and PsV were purified via OptiPrep gradient ultracentrifugation, as described previously (22) .
Animals. Female athymic NCr-nu/nu (nude) mice, aged 6 to 8 weeks, were obtained from the National Institutes of Health. The mice were housed and handled in accordance with the National Institutes of Health guidelines for the use and care of live animals, and all experimental protocols were approved by the National Cancer Institute's Animal Care and Use Committee.
All rabbit and rat polyclonal immune sera were generated by Lampire Biological Laboratories. To generate MusPV1 L1-specific polyclonal antisera, a New Zealand White rabbit or Sprague-Dawley rats were immunized every 3 weeks with 0.3 mg or 0.075 mg MusPV1 L1 virus-like particles, respectively, for a total of three doses. The rabbit polyclonal immune serum recognizing MusPV1 L2 was generated by immunization of a New Zealand White rabbit with a polypeptide comprising amino acids (aa) 17 to 36 of MusPV1 L2 coupled to keyhole limpet hemocyanin. Antigens were administered together with complete Freund's adjuvant for the priming dose and with incomplete Freund's adjuvant for each of the two booster doses, and exsanguination was performed 2 weeks after the final immunization.
Experimental in vivo transmission. For in vivo transmission experiments, the skin at the indicated locations on the mice was abraded using a hand rotary device with an attached felt wheel, and inoculation was performed 3 days later by scoring the prescarified areas and inoculating the scored sites as described previously (19) . In one set of transmission experiments, a sterile razor blade was scraped over the surface of a papillomatous lesion to loosen the uppermost layers of the epithelium, which were immediately transferred to prescarified muzzles of uninfected athymic NCr nude mice and inoculated by gentle scratching using the same blade.
Isolation of native MusPV1 virions. For the isolation of native MusPV1 virions, papillomatous tissues were cut into very fine pieces and were transferred to 2-ml microcentrifuge tubes, each containing a 7-mm stainless steel bead (Qiagen) and phosphate-buffered saline (PBS). The contents were homogenized in a universal laboratory mixer-mill disruptor (TissueLyser LT; Qiagen) for 1 min at 50 Hz. The tubes were then placed on dry ice for 10 min and were rethawed, and the procedure was repeated twice. After the three homogenization-freeze-thaw cycles, the steel beads were removed from the tubes and the homogenates subjected to sonication for 2 min at output level 3.0 (Misonix Sonicator 3000 with cup attachment). The suspensions were cleared by centrifugation for 10 min at 5,000 ϫ g and the supernatants collected. To remove any unpackaged, virion-associated DNA, these crude papilloma extracts were treated with Benzonase Nuclease, ultrapure (Sigma), at a final concentration of 0.1% (vol/vol) for 30 min at 37°C. Virions were purified from crude extracts by OptiPrep gradient centrifugation (22) .
L1-containing fractions were determined by Western blotting using the polyclonal rabbit immune serum (dilution, 1:1,000).
Viral copy numbers contained in the fractions were quantified after the liberation of encapsidated DNA from the viral capsids by proteinase K treatment as described in detail on the laboratory website (http://home .ccr.cancer.gov/Lco).
To obtain surface samples, sterile wooden cotton-tipped applicators (Greiner) were brushed with consistent force 20 times over the animals' skin surfaces. Sampling was performed prior to and 1 month and 3 months after infection, and samples were taken from the same areas of the same mice to ensure comparability. DNA was extracted from the swabs by using QIAquick PCR purification columns (Qiagen) with a final elution step in 50 l Tris-EDTA (TE) buffer, and copy numbers were determined. Samples were amplified with a DyNAmo SYBR green qPCR kit (Thermo Fisher Scientific Inc.) according to the manufacturer's instructions by using primers specific for MusPV1. The primer sequences are as follows: MusPV1-forward, 5=-GCCCGAAGACAACACCGCCACG-3=; MusPV1-reverse, 5=-CCTCCGCCTCGTCCCCAAATGG-3=. Viral copy numbers were calculated by comparison to known amounts of the religated MusPV1 genome.
Hematoxylin-and-eosin (HE) staining, immunofluorescent staining (IFS), and electron microscopy. Skin necropsy specimens were taken from the areas of interest and were snap-frozen in Tissue-Tek OCT compound freezing medium (Sakura Finetek USA Inc.) for HE staining or IFS (19) . To detect MusPV1 L1 proteins by IFS, ethanol-fixed tissue sections (thickness, 6 m) were stained with the rabbit or rat polyclonal immune serum directed against MusPV1 L1 at a dilution of 1:4,000 or 1:500, respectively. The rabbit polyclonal immune serum raised against MusPV1 L2 was used at a dilution of 1:500. Detection was performed with a donkey anti-rabbit or donkey-anti-rat secondary antibody conjugated to Alexa Fluor 488 or Alexa Fluor 594, as indicated, diluted 1:1,000 (Life Technologies). To visualize basal keratinocytes, sections were costained with a phycoerythrin (PE)-labeled antibody against CD49f (integrin ␣6) (BD Biosciences). Nuclei were counterstained by mounting sections with ProLong Gold antifade reagent containing 4=,6-diamidino-2-phenylindole (DAPI) (Life Technologies).
For in vitro IFS, HaCaT and Pam212 cells were seeded onto glass no. 01 coverslips in a 24-well plate at a density of 1 ϫ 10 5 cells per well and were cultured overnight. They were then transfected with expression plasmids encoding MusPV1 L1 or L2, or with a bicistronic plasmid that ensures that all transfected cells will express both proteins. At 24 h posttransfection, cells were fixed with ethanol and glycine and were processed for IFS. L1 was detected with the rat anti-L1 antiserum, and L2 was detected with the rabbit anti-L2 antiserum as described above.
Microscopic analyses were performed on a Zeiss LSM 510 UV system for tissues and a Zeiss 780 system for cells. Images were processed in Adobe Photoshop, and color levels were adjusted uniformly across experiments.
For electron microscopy analysis, skin tissues were fixed in 2% glutaraldehyde, followed by 2% osmium tetroxide, and wash steps were performed with 0.1 M cacodylate buffer. After serial dehydration in ethanol and propylene oxide, samples were embedded in EMbed 812 resin (Electron Microscopy Sciences), and thin sections of approximately 80 nm were obtained by utilizing a Leica Ultracut UCT ultramicrotome (Leica). Sections were placed on 300-mesh copper grids and were stained first with saturated uranyl acetate in 50% methanol and then with lead citrate. The grids were viewed in a JEM-1200 EXII electron microscope (JEOL Ltd.) at 80 kV, and images were recorded on an XR611M midmounted 10.5-Mpixel charge-coupled device (CCD) camera (Advanced Microscopy Techniques Corp.).
In vivo passive transfer. For in vivo passive transfer experiments, the indicated amounts of the rabbit polyclonal serum raised against MusPV1 L1 virus-like particles were diluted with sterile PBS to a final volume of 0.1 ml and were administered intraperitoneally to mice 24 h prior to infection. Serum obtained from a healthy, nonimmunized rabbit or PBS served as a specificity control. Infection was performed on the muzzles and tails of five mice for each group in two independent experiments. Animals were followed for a total of 3 months, papilloma outgrowth was recorded, and the lengths of tail lesions of papilloma-positive mice were quantified at the end of this period.
In vitro standard neutralization assays. Mouse sera were analyzed for the presence of neutralizing anti-MusPV1 antibodies as described previously (23) . The only modification was the use of phGluc (21), rather than secretory alkaline phosphatase (SEAP), as the reporter plasmid in the MusPV1 L1/L2 PsV. The 50% effective concentration (EC 50 ) titers, defined as the highest dilutions of sera at which the resulting relative light units are lower than 50% of the average signals in the negative controls lacking sera, were calculated using GraphPad Prism software, version 6.0.
In vivo imaging analysis. The copy numbers of the encapsidated reporter plasmid pCLucf, encoding firefly luciferase, in MusPV1 L1/L2 PsV preparations were quantified as described previously (19) . For in vivo imaging analysis, identical amounts (corresponding to 5.36 ϫ 10 10 reporter plasmids) of luciferase-transducing MusPV1 L1/L2 PsV were used to inoculate mice on the skin of their muzzles, tails, and backs as described previously (19) . Transduction was determined on day 3 postinoculation by intraperitoneal administration of 1.5 mg of the substrate D-luciferin (Caliper Life Sciences) per mouse. Images were taken 10 min later in an IVIS 100 imaging system (Caliper Life Sciences) in dorsal and ventral views with medium binning and 60 s of exposure. The average radiance (in photons per second per square centimeter per steradian [p/s/cm 2 /sr]) within the area of interest was determined with Living Image software, version 3.0 (Caliper Life Sciences), and the mean luminescence was calculated with GraphPad Prism, version 6.0.
Detection of MusPV1 E1ˆE4 spliced transcripts. To detect E1ˆE4 spliced transcripts of MusPV1 as a measure of initial infection, athymic NCr nude mice were concomitantly infected on the skin of their backs and tails. For infection of each site, 3.5 ϫ 10 9 MusPV1 virions were used, and skin tissues from the infected areas were harvested at day 4, day 14, and day 22 postinfection. Littermates that were mock infected with PBS were euthanized at each time point and served as negative controls. Total RNA was isolated from skin tissue specimens using TRI reagent (Molecular Research Center Inc.), treated with DNase I (Qiagen), and reverse transcribed into cDNA by using the SuperScript III first-strand synthesis system (Invitrogen) according to the manufacturers' instructions. Real-time PCR was performed in an ABI Prism 7900HT sequence detection system using the TaqMan Universal PCR master mix (Life Technologies). The primer sequences for the detection of MusPV1 E1ˆE4 spliced transcripts are as follows: E1ˆE4-forward, 5=-CATTCGAGTCAC TGCTTCTGC-3=; E1ˆE4-reverse, 5=-GATGCAGGTTTGTCGTTCTCC-3=; E1ˆE4-probe, 5=-6-carboxyfluorescein (FAM)-TGGAAAACGATAAA GCTCCTCCTCAGCC-6-carboxytetramethylrhodamine (TAMRA)-3=. The levels of MusPV1 E1ˆE4 spliced transcripts were calculated relative to those of the endogenous control, beta-actin (Life Technologies), in the same samples. Reactions were performed in triplicate for each primerprobe set, and all corresponding endogenous control and E1ˆE4 reactions were run on the same plate. In addition, MusPV1-specific viral copy numbers were quantified in these samples by using MusPV1-forward and MusPV1-reverse primers and were compared to defined amounts of the religated MusPV1 genome as standards, as stated above.
Statistical analyses. Statistical analyses (with Mann-Whitney tests) were performed using GraphPad Prism software, version 6.0 for Windows.
RESULTS

Generation of a synthetic full-length MusPV1 genome in vitro and papilloma formation in athymic NCr nude mice in vivo.
To determine whether a de novo-generated MusPV1 genome can induce papilloma formation, the genome was synthesized according to the published sequence (16) and was either circularized by intramolecular religation or encapsidated into L1/L2 capsids of the homologous virus MusPV1 or the heterologous virus HPV 16. The in vivo infectivities of these three preparations in immunodeficient, athymic NCr nude mice were evaluated by inoculating their muzzles, the location originally described for the spontaneous MusPV1-induced papillomas (13) , and following the animals for 3 months.
All three preparations gave rise to papillomas, confirmed histologically (data not shown), at the inoculation sites of each mouse: in 5/5 mice for naked MusPV1 DNA (Fig. 1A) , in 16/16 mice for the MusPV1 L1/L2 capsids encapsidating the genome (Fig. 1B) , and in 6/6 mice for the HPV 16 L1/L2 capsids encapsidating the genome (Fig. 1C) . Thus, the synthetic genomic MusPV1 DNA is pathogenic in the muzzle, whether it is delivered as naked DNA or encapsidated as homologous (MusPV1 L1/L2) or heterologous (HPV 16 L1/L2) quasivirions. For each preparation, lesions first became visible about 1 month after inoculation, continued to grow progressively, and did not regress spontaneously, even when some mice were observed for more than 9 months. The results with the homologous quasivirions were similar to those described initially for MusPV1 (13) .
When presumptive virions were extracted and partially purified from the lesions derived from each type of MusPV1 preparation, they were all found to contain abundant amounts of MusPV1 L1 protein (Fig. 1D, top) , and viral genomic DNA, as many as 10 13 viral copies per ml, as measured by real-time PCR (Fig. 1D, bottom) , was detected in the fractions purified from the papillomas. These results suggest that, as expected, all of the pap-illomas, whether they were induced by naked genomic DNA or by either of the quasivirions, expressed substantial amounts of native MusPV1 viral products.
Viral shedding and serial passaging in vivo. To test whether native virions isolated from the initial lesions could be serially passaged in vivo, prescarified muzzle skin of naive athymic NCr nude mice was infected with the purified MusPV1 preparations. All mice developed papillomas starting 3 to 4 weeks after inoculation ( Fig. 1E ; the mouse shown was inoculated with 1 ϫ 10 9 viral copies). The preparations have now been serially passaged 10 times with no apparent decrease in infectivity (Fig. 1F shows papillomas at passage 5).
To establish the lowest viral inoculum that could efficiently induce papilloma development, MusPV1 virions were serially diluted (10-fold), and decreasing doses were applied to individual mice. After an observation period of 2 months, the smallest amount of MusPV1 virions that was found to reproducibly and efficiently give rise to papillomas corresponded to 1 ϫ 10 7 viral copies (Fig. 1G) . The next-higher dilution (1 ϫ 10 6 viral copies) failed to reproducibly induce papilloma formation (data not shown).
To determine whether viral DNA was present at the surfaces of papillomas, newly infected athymic NCr nude mice were swabbed just prior to inoculation and at 1 and 3 months postinoculation. Consistent force and consistent numbers of strokes were applied to the same skin sites to allow comparison over time. The viral copy numbers from the extracted swab samples were determined by real-time PCR. As expected, the uninfected mice (day 0) did not have MusPV1 DNA on their skin (Fig. 1H) . However, swab samples taken 1 month or 3 months after infection showed about 4 ϫ 10 10 viral copies per swab ( Fig. 1H ; 5 mice/group). By the 3-month time point, all mice had developed prominent papillomas, demonstrating shedding of MusPV1 viral DNA from the surfaces of macroscopically visible lesions. In contrast to the immunodeficient athymic NCr nude mice, immunocompetent BALB/c mice (n ϭ 5) inoculated with the same amount of the same preparation of MusPV1 virions failed to develop visible lesions and also lacked detectable MusPV1 DNA in swabs taken at 1 month postinoculation (Fig. 1H ). Detailed follow-up studies of immunocompetent strains of mice will be reported separately (unpublished data).
To evaluate whether MusPV1 virions at the surfaces of lesions are infectious, a sterile scalpel blade was first scraped over the surface of a papilloma to abrade the uppermost layers of the epithelium and was then immediately scratched over prescarified skin of uninfected athymic NCr nude mice. Outgrowth of papillomas was observed in all inoculated (5/5) mice after 3 months (Fig. 1I) , suggesting that infectious virions may be shed from the surfaces of visible lesions in numbers high enough to induce papilloma formation.
Spontaneous and experimental infection of the tail. After infection of the muzzles of the mice, a spontaneous papillomatous lesion was observed on the tail of one animal. We therefore explored the susceptibility of the tail to experimental infection, because this anatomical location offers some advantages over the muzzle for observing papilloma development. While extensive papilloma growth on the muzzle hinders food intake, the tail can be easily scarified, evolving lesions are readily measured, and extensive growth in that location does not cause obvious distress.
Experimental inoculation of the tail indicated that its susceptibility to MusPV1-induced papilloma formation was similar to that of the muzzle ( Table 1 ). The lesions ( Fig. 2A) grew progressively, were verified histologically to be papillomas (Fig. 2B) , and contained densely packed, paracrystalline arrays of 50-to 60-nm viral particles in the nuclei of koilocytic cells by electron microscopy (Fig. 2C) . When the expression of L1 capsid protein in tail lesions was examined by fluorescence microscopy using a rabbit polyclonal serum raised against MusPV1 L1 virus-like particles, coincident visualization of basal keratinocytes with an anti-CD49f antibody demonstrated the presence of the MusPV1 L1 protein throughout the epithelium (Fig. 2D) . Furthermore, the L1 protein was unexpectedly localized to the cytoplasm in the lower layers, although there was strong nuclear L1 staining in the upper spinous and granular layers, suggesting active virion production and retention in these layers. These L1 protein results were specific, since no MusPV1 L1 protein was detected in sections taken from the tails of mock-infected control mice that had been inoculated with PBS (Fig. 2E) .
Passive transfer of a neutralizing, anti-MusPV1 L1 immune serum. To confirm that MusPV1 transmission was mediated by virions (as opposed to naked DNA), we sought to inhibit papilloma formation by passive transfer of a rabbit anti-MusPV1 L1 virus-like particle immune serum whose neutralizing activity (EC 50 titer, 5,684,000) had been determined in an in vitro neutralization assay that used MusPV1 L1/L2 PsV infection of 293TT cells. Athymic NCr nude mice received either the rabbit antiMusPV1 L1 immune serum, a control preimmune rabbit serum, or PBS 24 h prior to inoculation with 3.8 ϫ 10
10 MusPV1 virions at both the muzzle and the tail of each mouse. The mice were then observed for 3 months for the outgrowth of papillomas ( Table 2) . As expected, all animals (5/5) that received the control rabbit serum developed large papillomas at both sites. In contrast, passive Representative hematoxylin-and-eosin-stained tissue section taken from a tail papilloma (magnification, ϫ2.5). (C) Electron micrograph of the nucleus of a koilocyte (scale bar shown below). (D and E) Immunofluorescent staining of tail skin tissue sections taken on day 14 postinfection from a papilloma (D) or an uninfected control (E). Staining was performed with a rabbit immune serum directed against MusPV1 L1 virus-like particles, followed by an Alexa Fluor 488-conjugated second-step antibody (green). Basal keratinocytes were stained with a phycoerythrin-labeled antibody against CD49f (integrin ␣6) (red). transfer of 20 l of the anti-MusPV1 L1 rabbit immune serum inhibited papilloma formation: only one of the five mice in this group developed lesions, which were small papillomas on its muzzle and tail. The tail lesion in this mouse was 3 mm long, much shorter than the total length of the tail papillomas that developed in the mice that had received the control rabbit serum (290 mm) or PBS (291 mm) (P, 0.0079). The inhibitory effect of the rabbit anti-MusPV1 L1 immune serum was clearly dose dependent, since administration of 2 l of the anti-MusPV1 rabbit serum resulted in more lesions (6/10 positive sites) with larger tail papillomas (184 mm). The titer of circulating neutralizing anti-MusPV1 L1 antibodies in these mice was measured by the in vitro MusPV1 L1/L2 PsV neutralization assay. At the time of MusPV1 inoculation (day 0), all animals that had received the rabbit anti-MusPV1 L1 immune serum had measurable neutralizing titers (Fig. 3) . The mean EC 50 titers were 27,950, 340, and 312 for the 20-l, 2-l, and 0.2-l anti-MusPV1 L1 serum transfer groups, respectively. The similarity of the titers in the 2-l and 0.2-l groups probably accounts for the similarity of the papilloma data in these two groups ( Table 2) . As expected, all control groups lacked circulating neutralizing antibodies. However, 5 days after MusPV1 inoculation, neutralizing antibodies were detected in all groups, including the control animals that had received normal rabbit serum or PBS. This observation suggests that there was rapid, low level, and presumably transient T cell-independent antibody production in the athymic NCr mice in response to MusPV1 exposure.
Low efficiency of papilloma formation on the back. As noted above, papilloma formation by MusPV1 infection was very efficient on the muzzles and tails of athymic NCr nude mice: 93/93 (100%) mice whose muzzles were infected and 75/77 (97%) mice whose tails were infected developed at least one papilloma and usually several (Table 1 ). In contrast, the skin on the backs of the same mice was found to be relatively resistant to papilloma formation. After 31 attempts to induce papilloma outgrowth, only two relatively small papillomas were observed, although the same abrasion protocol and the same batch of MusPV1 virions were used at all three sites. The two papillomas were on the back of the same mouse (1/31 [3.2%]) (Fig. 4A) . HE staining of the sections taken from these small lesions showed histological features of papillomatous tissues, thus verifying the diagnosis (Fig. 4B) . Mockinfected control mice never developed lesions on their backs, as shown by HE staining (Fig. 4C) .
The resistance of the back skin was rather surprising, given the susceptibility of the muzzle and tail. Since the backs of immunocompetent BALB/c mice have been shown to be permissive to infection by PsV derived from different human and animal PV types, including MusPV1 (19), we next evaluated the susceptibility of the back skin of athymic NCr nude mice to MusPV1 PsV infection. MusPV1 PsV encapsidating a reporter plasmid encoding luciferase (corresponding to 5.36 ϫ 10 10 reporter plasmid copies for each area) were used to inoculate the prescarified skin of the backs, as well as the muzzles and tails, of the mice. PsV infection was evaluated by in vivo imaging analysis on day 3 postinoculation, because maximal luciferase expression for MusPV1 PsV in the skin of immunocompetent mice has been shown at this time (19) . Following systemic administration of the substrate D-luciferin, a luminescent signal was detected in all inoculated mice at all three sites (Fig. 5A and B, dorsal and ventral views, respectively), (Fig. 5C ) partly reflect the variable sizes of the inoculation areas due to anatomical differences and do not necessarily imply that one site is more or less susceptible than another.
Detection of MusPV1 E1ˆE4 spliced transcripts as a surrogate marker of viral infection. The fact that MusPV1 PsV can infect the skin on the tails, muzzles, and backs of athymic NCr nude mice suggested that the initial infectious entry steps of PV proceed equally at these sites. However, the low rate of papilloma formation on the back suggested that this region may be restricted for later steps in viral replication, unlike the tail and muzzle. We therefore investigated whether qualitative and/or quantitative differences exist between the viral transcription of native MusPV1 virions on the tail and the back.
Athymic NCr nude mice were simultaneously infected on the tails and backs with 3.5 ϫ 10 9 MusPV1 virions per site, and littermates that had been mock infected with PBS served as negative controls. The two sites were monitored for MusPV1 E1ˆE4 spliced transcripts, because such transcripts have frequently been used as a marker for initial PV infection (24, 25, 26) , and the number of viral transcripts in each sample was compared to the amount of endogenous control beta-actin in the sample. RNA was isolated from the sites on days 4, 14, and 22 following infection, and similar yields of 50 to 60 g/sample were obtained.
As expected, no papillomas developed on the back, while small papillomas were present on the tail in the majority of the mice at 14 days, and by day 22, the tails of all infected animals displayed clearly visible lesions (data not shown). Four days after infection, the numbers of MusPV1 E1ˆE4 spliced transcripts on the back and tail were very low, and they remained comparatively low on the back at later time points (Fig. 5D, bars) . In contrast, the numbers of MusPV1 E1ˆE4 spliced transcripts increased dramatically in the RNA from the tail on days 14 and 22, suggesting a higher level of viral transcription in the tail than in the back, a finding that was correlated with the presence of papillomas in the tail. Calculation of absolute viral copy numbers indicated that between days 4 and 14, there was an almost 20-fold increase in the copy number on the back (from 4.6 ϫ 10 3 to 9.8 ϫ 10 4 copies), with similar numbers present on day 22 (9.7 ϫ 10 4 copies) (Fig. 5D, numbers) . For the tail, the calculation of copy numbers confirmed the large progressive increase in the E1ˆE4/beta-actin transcript ratio seen at each time point and the much higher levels of virus on the tail than on the back on days 14 and 22. Differential expression of MusPV1 capsid proteins in the tail and back. As noted above, the major capsid protein, L1, was found unexpectedly to accumulate in the cytoplasm of cells in the lower epithelial layers of the skin (Fig. 2D) . To explore this phenomenon in greater detail, we analyzed the expression of L1 in the tail and back by IFS at 4, 14, and 22 days after infection, and basal keratinocytes were visualized by costaining with an anti-CD49f antibody. Of note, the differences in morphology between the tissues taken from the same region are attributable to the stages of wound healing after scarification. Consistent with the very low expression of the E1ˆE4 spliced transcripts at both locations on day 4, L1 capsid protein was not observed in tissue sections taken from either infected tails (Fig. 6A) or infected backs (Fig. 6B) at this time point. However, L1 was readily detected at both sites at later time points, indicating its de novo production, while the uninfected controls remained L1 negative at these time points ( Fig. 6G and H ; tissues taken on day 22 are shown as representatives). In infected tails on days 14 and 22, there was abundant L1 throughout the epithelium ( Fig. 6C and E) . As noted above, the L1 was distributed predominantly in a punctate pattern in the cytoplasm of keratinocytes in the lower epithelial layers, whereas strong and pronounced nuclear L1 staining was present in the upper spinous and granular layers. No L1 staining was found in the dermal compartment, although seemingly positive staining could sometimes be observed below the basal layers, a finding attributable to the (trans-)sectioning of the papilloma's deregulated architecture. The infected skin of the backs of the same mice contained lower levels of L1 on days 14 and 22, and it was localized to the cytoplasm of the keratinocytes (Fig. 6D and F) . In addition, in the tissue taken on day 22, isolated specific L1 nuclear positivity and some staining of the squames were observed; the latter phenomenon is frequently observed in infected skin tissues (Fig. 6F) . The L1-positive squames presumably contain virions in the final stages before shedding.
To correlate the observed localization of L1 with the expression of the minor capsid protein, L2, we examined the distribution of the two proteins in both sites at day 14. In the tail skin, L2 was readily detectable and was highly expressed in the nuclei of keratinocytes in the upper epithelial layers (Fig. 7A) , while the localization of L1 to the cytoplasm or nucleus depended on the epithelial layer, as described above (Fig. 7B) . Double staining revealed that L1 and L2 colocalized in the nuclei of upper-layer keratinocytes (Fig. 7C) . In a few cells, nuclear L2 staining was observed with cytoplasmic L1, but nuclear L1 protein was not found in the absence of nuclear L2 protein (Fig. 7C) .
In the back skin, L2 expression was nearly undetectable, while
FIG 6
Immunofluorescent staining of skin tissues taken from the tails or backs of athymic NCr-nu/nu mice after infection with 3.5 ϫ 10 9 MusPV1 virions per site. Tissues were taken on day 4 after infection from the tails (A) or backs (B) of infected mice, on day 14 from the tails (C) or backs (D), and on day 22 from the tails (E) or backs (F). Skin taken on day 22 from the tails (G) or backs (H) of mock-infected mice served as representative controls. Staining was performed with a rabbit polyclonal immune serum raised against MusPV1 L1, which was detected with an Alexa Fluor 488-labeled secondary antibody (green). To determine the localization of MusPV1 L1 in relation to basal keratinocytes, sections were costained with a phycoerythrin-conjugated antibody against CD49f (integrin ␣6) (red). The epidermal compartment of the papilloma is shown in the upper part of each image and the dermal compartment in the lower part.
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December 2013 Volume 87 Number 24 jvi.asm.org 13221 L1 expression was reduced, as described above ( Fig. 7E and F) . The majority of keratinocytes showed moderate levels of L1 in their cytoplasm and no L2, although a few L2-expressing keratinocytes were found in the uppermost superficial layers (Fig. 7E ). In contrast to the many L2-expressing cells per section seen in the tail, the scanning of 25 sections from the back revealed only 2 cells that were positive for L2 (Fig. 7E) . In these cells, L2 expression was entirely nuclear. Interestingly, these were the only cells that contained nuclear L1 ( Fig. 7F and G) . To determine if MusPV1 L2 expression is an absolute requirement for the nuclear localization of MusPV1 L1, we investigated the localization of L1 and L2 in vitro. The immortalized keratinocyte cell lines HaCaT (human) and Pam212 (mouse) were transfected with expression plasmids for MusPV1 L1, L2, or L1 and L2 together on a bicistronic plasmid. In contrast to what was observed in the backs and tails, L1 expression alone was found to be predominantly nuclear in the cultured cell lines. This pattern was unchanged in cells coexpressing L1 and L2. Staining of HaCaT cells is shown in Fig. 8A and B. The results in Pam212 cells were identical (data not shown). L2 staining was also nuclear under all conditions (data not shown).
DISCUSSION
In this study, we have demonstrated that MusPV1 infection is a tractable system for the study of PV biology in the athymic NCr nude laboratory mouse, determined that the tail is as susceptible as the muzzle to MusPV1 infection, and, unexpectedly, observed that the back of the mouse is relatively resistant to MusPV1-induced papillomas and full viral replication. The findings for the back were correlated with drastically reduced expression of the E1ˆE4 spliced transcript and the minor capsid protein, L2, in this site compared with expression in the tail. Furthermore, the L1 protein is expressed throughout the epithelium and is cytoplasmic in the absence of the L2 protein, while in most cells that coexpress L1 and L2, L1 is found in the nucleus in conjunction with L2.
Previous studies have indicated that inoculation of the muzzles of immunosuppressed mice with MusPV1 can induce papillomas (13, 14) . In addition to confirming this observation, we demonstrated that cell extracts of these papillomas can undergo at least 10 serial passages with no loss of biological potency, and we confirmed that infection is virion dependent, since it was prevented by passive transfer of an immune serum raised against the MusPV1 major capsid protein, L1. We also found that the tail, a site that is easier to observe and sample than the muzzle, is susceptible to the development of MusPV1-induced papillomas.
In agreement with a recent report (15) , autoinoculation was observed in some mice, implying that minor abrasions and trauma can facilitate the spread of MusPV1. On the muzzle, papillomas occasionally arose not only at the inoculation site (the mucocutaneous border right below the lower lip) but also on the upper lip (best seen in Fig. 1C ). The susceptibility of the tail to MusPV1 was first suggested by the spontaneous development of a papilloma on the tail of a mouse that had been inoculated on the muzzle and housed with cage mates also inoculated on the muzzle. Furthermore, tail lesions frequently covered the entire length of the tail, although the area of inoculation was restricted to 0.5 to 1 cm at the base of the tail.
Although papillomas were efficiently induced in the muzzle and tail, the back was far less permissive. This phenomenon is not likely to be due to insufficient scarification and the resulting lack of access of the virions to the basal cells of the back skin, because in mice more epidermal layers are found in tail skin than in back skin (about 5 to 7 epidermal layers versus about 2 to 3 epidermal layers, respectively) (27) , and tail and muzzle skin is reported to have a thicker epidermis than the skin on the trunk (28) . Furthermore, the results described here clearly demonstrate that the virus was sufficiently delivered to the back skin, since the increases in the levels of MusPV1 E1ˆE4 spliced transcripts (130-to 170-fold) and in viral copy numbers (about 20-fold) in the back at later time points (day 14 and day 22 compared to day 4 postinfection) indicate low-level viral replication in the tissues after inoculation. Likewise, positive L1 staining can observed in the back skin at later time points (day 14 and day 22); this observation is not attributable to input virus, because L1 staining was absent at an earlier time point (day 4). Furthermore, analysis with MusPV1 L1/L2 PsV clearly indicated that the epithelial cells in all three locations could be readily transduced by this PsV. Because successful infection by PsV depends strictly on disruption of the epithelium and subsequent access to the basement membrane (20, 29, 30) , and infection of basal cells by MusPV1 PsV encompassing a reporter plasmid has been demonstrated after scarification (19) , this observation further corroborates adequate delivery of the MusPV1 genome to the target cells. Since PsV carry out the early entry steps in the PV life cycle, these results strongly suggest that region-specific differences in an intracellular factor(s) may be responsible for the observed resistance of the back to papilloma formation by native MusPV1. In a recent publication, Cladel et al. (15) used the backs of mice as the primary site of MusPV1 inoculation. In contrast to our results, these authors reported the development of visible lesions on the back that diminished over time. Since they also infected immunocompromised mice, it is not clear what caused this regression, although it may be related to their having inoculated the back.
The relatively low viral genome copy numbers and capsid protein levels after inoculation of the back with the virus may be direct results of the restricted production of E1ˆE4 transcripts at this site. Previous studies have shown that mutant HPV 18 and HPV 31 genomes in which the expression of E1ˆE4 transcripts is abrogated have reduced levels of viral DNA amplification and late gene expression following induction of keratinocyte differentiation in vitro (31) . The mechanistic basis for transcription restriction in the keratinocytes of the back remains to be elucidated. Based on previous in vitro studies of the differentiation-dependent gene expression of HPVs, it is possible that region-dependent differences in the binding of transcription factors and/or histone modification of the viral genome may play a role (32) . Consistent with this possibility, there is region-specific gene expression in skin, a process that can be regulated by the dermal fibroblasts, at least in part through region-specific expression of various Hox family transcription factors (33) .
Region-specific infection by PVs has been recognized for at least 70 years, following the demonstration that CRPV and rabbit oral papillomavirus (ROPV) infect nonoverlapping epithelial tissues (34) . The observed tissue or cell type specificity of PV has been attributed to the enhancer elements present in the long control region (LCR) or upstream regulatory region of PV (35) , which play a role in the expression of the viral genes after virus infection (1), and to tissue-restricted cellular transcription factors (36, 37, 38, 39) . The region-specific ability of genital and nongenital HPVs to cause, respectively, genital and nongenital warts may be analogous to the phenomenon identified here for MusPV1 on the muzzle and tail versus the back. The likelihood that region-dependent susceptibility to different HPVs is attributable to intracellular factors is supported by our previous observation that PsV of different PV types and species display similar susceptibilities for transduction in murine skin and therefore, by extension, in human skin (19) . The MusPV1 system described here makes it possible for the first time to take advantage of the plethora of available mouse reagents in order to understand this specificity at a mechanistic level, in contrast to the other examples of PV regional specificity, which have remained phenomenologic observations. We also observed that the MusPV1 L1 protein was abundantly expressed in all layers of the stratified squamous epithelium of the tail and, more unexpectedly, was localized to the cytoplasm in the lower epithelial layers, prior to expression of the L2 protein, which was not detected until the upper spinous and granular layers. In infections induced by high-risk PV types, neither L1 nor L2 is detected in the lower epithelial layers, and L2 protein expression is typically initiated prior to those layers where L1 is observed (40) . However, in cutaneous warts induced by HPV 1, L1 is expressed throughout the epithelium, in lower layers than L2 (41), a pattern similar to what we have observed here for MusPV1. In contrast to what we have observed with MusPV1, the HPV 1 L1 protein in warts is localized to the nucleus, even in the layers that do not contain detectable L2. Indeed, we are unaware of a PV other than MusPV1 in which L1 is reported to be found in the cytoplasm. It may be noted that this distribution of L1 may appear to differ from what has been described previously for MusPV1-induced lesions, where PV-specific antigens were found in the nuclei of cells in the stratum granulosum in the spontaneous papilloma found in the original immunodeficient mouse colony (13) and in papillomas experimentally induced by MusPV1 (14) . However, those studies used rabbit polyclonal antibodies raised against disrupted virions of canine cutaneous PV type 2 for the immunohistochemical staining, so it is not clear whether they recognize MusPV1 L1, L2, or both proteins. In this study, we employed an immune serum that specifically recognized conformationally correct MusPV1 L1, so it may have greater sensitivity and specificity in detecting the MusPV1 L1 protein.
Given that the L2 protein was localized to the nucleus and that nuclear L1 was detected only in cells that coexpressed L2, it is attractive to speculate that L2 may direct the nuclear localization of L1, although MusPV1 L1 contains a strong consensus nuclear localization signal, RGVKRAASTTSASSRRVVKRKRGSK (prediction performed using cNLS Mapper [http://nls-mapper.iab .keio.ac.jp/cgi-bin/NLS_Mapper_form.cgi] [42] ). Alternatively, the results could reflect differentiation-dependent changes in the cellular microenvironment, which coincidentally result in L2 expression and L1 nuclear localization. However, the latter possibility seems less likely, because on the back, where L2 expression is much lower, L1 was found in the cytoplasm throughout the epithelium, except in the very few cells that also contained nuclear L2. Interestingly, the in vivo situation with L1 was not mimicked with cultured mouse and human epithelial cells, where L1 was localized to the nucleus in cells transfected with an L1 expression plasmid, demonstrating that MusPV1 L1 has the intrinsic capacity to enter the nucleus. However, in MusPV1-infected tissues, cellular factors specific to an intact epithelium or additional viral proteins apparently restrict MusPV1 L1 localization to the cytoplasm in the lower layers of the epidermis.
Taken together, our findings support the hypothesis that, in skin tissues that are susceptible to MusPV1 infection, L1 is prevented from nuclear accumulation and thus from assembly into capsids by specific cytoplasmic retention signals. The subsequent expression of L2 in the upper spinous and granular epithelial layers would then trigger the transport of L1 capsomers into the nuclei of the differentiating keratinocytes, perhaps via karyopherins (43) and/or inducible HSP70 (44) , to assemble into infectious virions that have encapsidated the viral genome. It remains to be determined whether this translocation depends on a direct interaction between L1 and L2, as apparently can occur with HPV 33 (45) , or on an indirect mechanism. In the less permissive skin of the back, the infection program appears to be more defective for L2 expression than for L1 expression, which could effectively preclude virion formation at this site.
Our results also have implications regarding the fidelity of the biological properties of high-titer PsV and quasivirions produced in cultured cells, compared with those of native virions, since the MusPV1 system described here represents a rigorous comparison between these different types of viral preparations. In the studies conducted here, the properties of quasivirions were indistinguishable from those of native virions isolated from papillomas. Furthermore, we were able to confirm with native virions the inference that PsV faithfully mimic the initial steps of PV infection, supporting the conclusion that tissue tropism is determined by steps that lie beyond virion cell surface binding and entry into cells (19) .
